332 related articles for article (PubMed ID: 17031467)
1. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
Poggi A; Zocchi MR
Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
[TBL] [Abstract][Full Text] [Related]
2. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
[TBL] [Abstract][Full Text] [Related]
3. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation.
Contini P; Ghio M; Poggi A; Filaci G; Indiveri F; Ferrone S; Puppo F
Eur J Immunol; 2003 Jan; 33(1):125-34. PubMed ID: 12594841
[TBL] [Abstract][Full Text] [Related]
4. Tumor escape from immune surveillance.
Costello RT; Gastaut JA; Olive D
Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
[TBL] [Abstract][Full Text] [Related]
5. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
Maccalli C; Scaramuzza S; Parmiani G
Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A regulates human NK cell apoptosis induced by soluble HLA-I or by target cells.
Poggi A; Zocchi MR
Autoimmun Rev; 2005 Nov; 4(8):532-6. PubMed ID: 16214091
[TBL] [Abstract][Full Text] [Related]
7. NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells.
Poggi A; Prevosto C; Zancolli M; Canevali P; Musso A; Zocchi MR
Ann N Y Acad Sci; 2007 Aug; 1109():47-57. PubMed ID: 17785290
[TBL] [Abstract][Full Text] [Related]
8. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.
Kim R; Emi M; Tanabe K; Uchida Y; Toge T
Cancer; 2004 Jun; 100(11):2281-91. PubMed ID: 15160330
[TBL] [Abstract][Full Text] [Related]
9. Regulation of gammadelta T cell survival by soluble HLA-I: involvement of CD8 and activating killer Ig-like receptors.
Poggi A; Contini P; Catellani S; Setti M; Murdaca G; Zocchi MR
Eur J Immunol; 2005 Sep; 35(9):2670-8. PubMed ID: 16114098
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Kopp HG; Placke T; Salih HR
Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(4):377-86. PubMed ID: 17051976
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
13. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers.
Kassouf N; Thornhill MH
Oral Oncol; 2008 Jul; 44(7):672-82. PubMed ID: 17996489
[TBL] [Abstract][Full Text] [Related]
14. NKG2D ligands in tumor immunity.
Nausch N; Cerwenka A
Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
[TBL] [Abstract][Full Text] [Related]
15. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells.
Chang LY; Lin YC; Mahalingam J; Huang CT; Chen TW; Kang CW; Peng HM; Chu YY; Chiang JM; Dutta A; Day YJ; Chen TC; Yeh CT; Lin CY
Cancer Res; 2012 Mar; 72(5):1092-102. PubMed ID: 22282655
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma production in human NK cells through the engagement of CD8 by soluble or surface HLA class I molecules.
Spaggiari GM; Contini P; Negrini S; Dondero A; Carosio R; Ghio M; Puppo F; Indiveri F; Zocchi MR; Poggi A
Eur J Immunol; 2003 Nov; 33(11):3049-59. PubMed ID: 14579273
[TBL] [Abstract][Full Text] [Related]
17. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment and immune escape.
Ferrone S; Whiteside TL
Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
[TBL] [Abstract][Full Text] [Related]
19. Structural immunology and crystallography help immunologists see the immune system in action: how T and NK cells touch their ligands.
Chen Y; Shi Y; Cheng H; An YQ; Gao GF
IUBMB Life; 2009 Jun; 61(6):579-90. PubMed ID: 19472182
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells.
Poggi A; Musso A; Dapino I; Zocchi MR
Immunol Lett; 2014; 159(1-2):55-72. PubMed ID: 24657523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
